88 related articles for article (PubMed ID: 22266863)
61. Adaptive responses to dasatinib-treated lung squamous cell cancer cells harboring DDR2 mutations.
Bai Y; Kim JY; Watters JM; Fang B; Kinose F; Song L; Koomen JM; Teer JK; Fisher K; Chen YA; Rix U; Haura EB
Cancer Res; 2014 Dec; 74(24):7217-7228. PubMed ID: 25348954
[TBL] [Abstract][Full Text] [Related]
62. A new target for therapy in squamous cell carcinoma of the lung.
Ohashi K; Pao W
Cancer Discov; 2011 Jun; 1(1):23-4. PubMed ID: 22586316
[TBL] [Abstract][Full Text] [Related]
63. Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer.
Hammerman PS; Sos ML; Ramos AH; Xu C; Dutt A; Zhou W; Brace LE; Woods BA; Lin W; Zhang J; Deng X; Lim SM; Heynck S; Peifer M; Simard JR; Lawrence MS; Onofrio RC; Salvesen HB; Seidel D; Zander T; Heuckmann JM; Soltermann A; Moch H; Koker M; Leenders F; Gabler F; Querings S; Ansén S; Brambilla E; Brambilla C; Lorimier P; Brustugun OT; Helland A; Petersen I; Clement JH; Groen H; Timens W; Sietsma H; Stoelben E; Wolf J; Beer DG; Tsao MS; Hanna M; Hatton C; Eck MJ; Janne PA; Johnson BE; Winckler W; Greulich H; Bass AJ; Cho J; Rauh D; Gray NS; Wong KK; Haura EB; Thomas RK; Meyerson M
Cancer Discov; 2011 Jun; 1(1):78-89. PubMed ID: 22328973
[TBL] [Abstract][Full Text] [Related]
64. Genetic insight and therapeutic targets in squamous-cell lung cancer.
Sos ML; Thomas RK
Oncogene; 2012 Nov; 31(46):4811-4. PubMed ID: 22266863
[TBL] [Abstract][Full Text] [Related]
65. [Advances of molecular targeted therapy in squamous cell lung cancer].
Ma L; Zhang S
Zhongguo Fei Ai Za Zhi; 2013 Dec; 16(12):671-5. PubMed ID: 24345494
[TBL] [Abstract][Full Text] [Related]
66. Discoidin domain receptor 2 signaling networks and therapy in lung cancer.
Payne LS; Huang PH
J Thorac Oncol; 2014 Jun; 9(6):900-4. PubMed ID: 24828669
[TBL] [Abstract][Full Text] [Related]
67. Anaplastic lymphoma kinase rearrangement in lung cancer: its biological and clinical significance.
Toyokawa G; Seto T
Respir Investig; 2014 Nov; 52(6):330-8. PubMed ID: 25453376
[TBL] [Abstract][Full Text] [Related]
68. Treatment of advanced non-small-cell lung cancer with epidermal growth factor receptor (EGFR) mutation or ALK gene rearrangement: results of an international expert panel meeting of the Italian Association of Thoracic Oncology.
Gridelli C; de Marinis F; Cappuzzo F; Di Maio M; Hirsch FR; Mok T; Morgillo F; Rosell R; Spigel DR; Yang JC; Ciardiello F
Clin Lung Cancer; 2014 May; 15(3):173-81. PubMed ID: 24486058
[TBL] [Abstract][Full Text] [Related]
69. Beyond EGFR and ALK inhibition: unravelling and exploiting novel genetic alterations in advanced non small-cell lung cancer.
Califano R; Abidin A; Tariq NU; Economopoulou P; Metro G; Mountzios G
Cancer Treat Rev; 2015 May; 41(5):401-11. PubMed ID: 25842168
[TBL] [Abstract][Full Text] [Related]
70. Squamous-cell carcinomas of the lung: emerging biology, controversies, and the promise of targeted therapy.
Drilon A; Rekhtman N; Ladanyi M; Paik P
Lancet Oncol; 2012 Oct; 13(10):e418-26. PubMed ID: 23026827
[TBL] [Abstract][Full Text] [Related]
71. Targeting fibroblast growth factor receptor and discoidin domain receptor 2 in non-small-cell lung cancer.
Riess JW; Neal JW
J Thorac Oncol; 2012 Dec; 7(16 Suppl 5):S385-6. PubMed ID: 23160327
[No Abstract] [Full Text] [Related]
72. Adjuvant therapy for EGFR mutant and ALK positive NSCLC: Current data and future prospects.
Chuang JC; Neal JW; Niu XM; Wakelee HA
Lung Cancer; 2015 Oct; 90(1):1-7. PubMed ID: 26275476
[TBL] [Abstract][Full Text] [Related]
73. Overcoming the resistance to crizotinib in patients with non-small cell lung cancer harboring EML4/ALK translocation.
Perez CA; Velez M; Raez LE; Santos ES
Lung Cancer; 2014 May; 84(2):110-5. PubMed ID: 24598368
[TBL] [Abstract][Full Text] [Related]
74. Anaplastic lymphoma kinase as a new target for the treatment of non-small-cell lung cancer.
Tiseo M; Gelsomino F; Bartolotti M; Bordi P; Bersanelli M; Rossi G; Ardizzoni A
Expert Rev Anticancer Ther; 2011 Nov; 11(11):1677-87. PubMed ID: 22050016
[TBL] [Abstract][Full Text] [Related]
75. New targets and new mechanisms in lung cancer.
Carrizosa DR; Mileham KF; Haggstrom DE
Oncology (Williston Park); 2013 May; 27(5):396-404. PubMed ID: 25184262
[TBL] [Abstract][Full Text] [Related]
76.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
77.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
78.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]